Ripk3 signaling represses the development of such sub-types of AML by stimulating Mlkl-mediated necroptosis and IL-1β-induced differentiation of pre-leukemia stem cells (pre-LSCs) as demonstrated in mouse models (Hockendorf et al., 2016). Here, RIPK3 is linked to leukemia.